[{"from": "human", "value": "Please give me some details about this molecule. [C][C][Branch1][C][C][Branch1][C][C][C][=C][C][=Branch1][Branch1][=N][O][Ring1][Branch1][N][C][=Branch1][C][=O][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=C][N][C][=C][Branch2][Ring1][Ring2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][N][C][C][O][C][C][Ring1][=Branch1][S][C][Ring2][Ring1][C][=N][Ring2][Ring1][Branch1].[Cl].[Cl]"}, {"from": "gpt", "value": "The molecule is the dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases."}]